The study of the difference between vascular and biological age among patients with arterial hypertension after optimal antihypertensive and hypolipidemic treatment

Aim: The purpose of this study was to assess the difference between Vascular (VA) and Biological age (BA) among pts with arterial hypertension (AH) after optimal antihypertensive and hypolipidemic treatment.

Material and Methods: The current non-interventional study began in February 2019 and 200 patients (pts) were included in the study. At Visit 1 the doctor collected information on age, sex, early family history of cardiovascular diseases (CVD), diabetes mellitus (DM) and other CV risk factors, smoking habits, obesity, BP values, lipid levels: low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG), SCORE scale for non- interventional study. The information was collected on CV risk and VA as well. Pts have been prescribed treatment with rosuvastatin, valsartan (Val), or Val/ hydrochlorothiazide (HCTZ), or amlodipine (Aml). At Visit 2 the doctor collected information on BP values, lipid levels: LDL-C, HDL-C, and TG.

Results: Total VA was initially 73.8 ± 2.2 y.o., after treatment 65.5 ± 1.8 y.o. (p<0.001), the difference between VA and BA was initially 13.7 ± 1.2 y., after treatment 5.6 ± 0.8 y.

Conclusion: The difference between VA and BA among pts with AH was reduced by almost 2.5 times as a result of optimal antihypertensive and hypolipidemic treatment (p< 0.001).